Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leg artery trouble may signal hidden heart damage

NCT ID NCT06215248

Knowledge-focused Sponsor: Tartu University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how narrowed leg arteries (peripheral artery disease) might affect heart function. Researchers will use advanced heart ultrasound to measure subtle changes in heart muscle strain in 162 participants. They will also check for links to metabolism and organ damage. The goal is to better understand the heart risks tied to leg artery disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors detect early heart problems in people with leg artery disease, leading to better monitoring and care.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with cardiovascular risk factors

Ages

35 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria in LEAD group: * Fontaine I-IV class symptoms * Confirmed diagnosis of LEAD Inclusion Criteria in control group: * Age 35-85 * Has to have at least of the following: hypertension, diabetes, coronary artery disease or the patient smokes Exclusion Criteria: * Age \<35 or \>85 years * BMI ≥40 kg/m² * Known heart failure in history * Any acute or chronic autoimmune or rheumatic disease * Cardiac structural disease in history: inflammatory, infiltrative diseases, nonischemic cardiomyopathies * Acute coronary syndrome in last 3 months * Moderate to severe cardiac valvular disease * Cardiac valvular disease operative/invasive treatment in history * Cardiac implantable electronic device (CIED) * Transitory ischemic attack or stroke in last 3 months * Severe COPD (GOLD C or D) * Moderate to severe asthma (according to GINA 2022 criteria) * Untreated hypertension (noninvasive blood pressure measurement ≥180/110 mmHg during recruitment) * Chronic severe kidney dysfunction (eGFR \<30 ml/min/1,73 m²) * Malignant tumor with radiation treatment to thorax, oncologic or biologic treatment in history * Chronic hematologic disease (except for anemia) * Severe liver dysfunction * Malignant tumor with \<5 years of remission * Acute or chronic infectious disease * Anemia with hemoglobin \<80 g/L

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Peripheral artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tartu University Hospital

    RECRUITING

    Tartu, Estonia

More trials for these conditions

Other studies related to the condition(s) this trial covers.